Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 2Phase 3 1Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Neoplasm Metastasis 1

Interventions

Specimen Handling 45pembrolizumab 40Magnetic Resonance Spectroscopy 32Cyclophosphamide 31Biopsy 31fludarabine 27Cetuximab 19Cisplatin 18Carboplatin 18atezolizumab 15Bevacizumab 15Fluorouracil 14venetoclax 13Radiation 13Leucovorin 13fludarabine phosphate 12Radiotherapy 12Gemcitabine 12Pemetrexed 11Oxaliplatin 11Nivolumab 11Cytarabine 10130-nm albumin-bound paclitaxel 10Prednisone 9Paclitaxel 9Irinotecan 9Fulvestrant 9Radiosurgery 8Platinum 8Immunoglobulin G 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × cediranib × 30 days × Clear all
NCT00750841 2026-05-19

Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours

AstraZeneca

Phase 1 Active not recruiting
64 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡